Author:
Beale Sophie,Dickson Rumona,Bagust Adrian,Blundell Michaela,Dundar Yenal,Boland Angela,Marshall Ernie,Plummer Ruth,Proudlove Chris
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Pharmacology
Reference23 articles.
1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. 2009. http://www.nice.org.uk/media/913/06/guide_to_the_sta-proof_6-26-10-09.pdf . Accessed 12 Sept 2013.
2. National Institute for Health and Clinical Excellence. Melanoma (BRAF V600 mutation positive, unresetable metastatic) - vemurafenib (TA269). 2011. http://guidance.nice.org.uk/TA269 . Accessed 12 Sept 2013.
3. Dickson R, Bagust A, Boland A, Blundell M, Davis H, Dundar Y, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy. Pharmacoeconomics. 2011;29(12):1–12.
4. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, et al. Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma. PharmacoEconomics. 2013;31:403–13. doi: 10.1007/s40273-013-0043-8 .
5. Parkin D, Mesher D, Sasieni P. Cancers attributable to solar (ultraviolet) radiation exposure in the UK in 2010. Br J Cancer. 2011;31:403–13. doi: 10.1007/s40273-013-0043-8 .
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献